{"id":"carvedilol-alone","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Dizziness"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Erectile dysfunction"},{"rate":"1-2","effect":"Bronchospasm"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carvedilol blocks beta-1, beta-2, and alpha-1 adrenergic receptors, reducing sympathetic nervous system activity on the heart and blood vessels. This dual action decreases heart rate and contractility while causing vasodilation, making it effective for managing hypertension and heart failure by reducing cardiac oxygen demand and improving ventricular remodeling.","oneSentence":"Carvedilol is a non-selective beta-adrenergic receptor antagonist with alpha-1 blocking properties that reduces heart rate, blood pressure, and cardiac workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:44.713Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Left ventricular dysfunction post-myocardial infarction"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT07465471","phase":"NA","title":"Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2026-03-01","conditions":"Liver Cirrhosis","enrollment":210},{"nctId":"NCT07445334","phase":"NA","title":"Catheter Ablation Versus Anti-arrhythmic Drugs for Premature Ventricular Complexes","status":"NOT_YET_RECRUITING","sponsor":"Western Sydney Local Health District","startDate":"2026-03-01","conditions":"Premature Ventricular Complexes, Premature Ventricular Contraction (PVC), Premature Ventricular Beats","enrollment":40},{"nctId":"NCT07350070","phase":"PHASE2","title":"TACE Combined With Tislelizumab, Lenvatinib, and Carvedilol for Unresectable HCC With Cirrhotic Portal Hypertension","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-31","conditions":"HCC, Liver Cirrhosis, Portal Hypertension","enrollment":78},{"nctId":"NCT07352228","phase":"PHASE4","title":"Carvedilol vs. Propranolol for Preventing Rebleeding After Endoscopic Treatment of Cirrhotic Varices","status":"ENROLLING_BY_INVITATION","sponsor":"Xijing Hospital","startDate":"2026-01-01","conditions":"Rebleeding of Portal Hypertension in Liver Cirrhosis, Propranolol, Carvedilol","enrollment":350},{"nctId":"NCT07322237","phase":"PHASE4","title":"DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors","enrollment":400},{"nctId":"NCT05019027","phase":"PHASE4","title":"N-of-1 for Beta-Blockers in Cardiac Amyloidosis","status":"ENROLLING_BY_INVITATION","sponsor":"Weill Medical College of Cornell University","startDate":"2024-01-31","conditions":"Cardiac Amyloidosis, Heart Diseases, TTR Cardiac Amyloidosis","enrollment":20},{"nctId":"NCT06861075","phase":"NA","title":"CARPEUS : Effect of Carvedilol on the Portosystemic Gradient as Measured by Endoscopic Ultrasound","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-04-16","conditions":"Cirrhosis, Portal Hypertension Related to Cirrhosis","enrollment":30},{"nctId":"NCT07108075","phase":"NA","title":"Acute Portal Pressure Reduction by Metformin and Carvedilol Compared to Carvedilol Alone in Cirrhosis.","status":"RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-06-14","conditions":"Liver Cirrhosis","enrollment":72},{"nctId":"NCT06431919","phase":"NA","title":"Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2025-06-10","conditions":"Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver","enrollment":260},{"nctId":"NCT06576934","phase":"NA","title":"Early TIPS in Patients With Liver Cirrhosis and Ascites","status":"RECRUITING","sponsor":"University Hospital Freiburg","startDate":"2025-04-01","conditions":"Liver Cirrhosis, Ascites Hepatic, Portal Hypertension","enrollment":134},{"nctId":"NCT04345796","phase":"PHASE3","title":"Pharmacological Reduction of Right Ventricular Enlargement","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2021-02-15","conditions":"Tricuspid Regurgitation, Right Ventricular Dilatation","enrollment":56},{"nctId":"NCT06594783","phase":"PHASE4","title":"Carvedilol Plus EVL or Not for the Primary Prevention of Esophageal Variceal Bleeding in Carvedilol Non-responders","status":"RECRUITING","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2025-01-06","conditions":"Cirrhosis, Esophageal Varices","enrollment":80},{"nctId":"NCT06664307","phase":"","title":"Evaluation of the Efficacy and Safety of Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS) in the Therapeutic Algorithm of Patients with Liver Cirrhosis.","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitario Virgen Macarena","startDate":"2024-11-01","conditions":"Portal Pressure Gradient (PPG) Measurement Guided by Endoscopic Ultrasound (EUS), Hepatic Cirrhosis","enrollment":35},{"nctId":"NCT05849766","phase":"PHASE3","title":"Effect of Dapagliflozin on Cardiac Structure, Function and Secondary Mitral Regurgitation in Patients with Left Ventricle Dysfunction","status":"COMPLETED","sponsor":"October 6 University","startDate":"2023-04-27","conditions":"Dilated Cardiomyopathy","enrollment":150},{"nctId":"NCT00834795","phase":"PHASE1","title":"Carvedilol 25 mg in 36 Fasted, Healthy, Adult Subjects","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-12","conditions":"Healthy","enrollment":36},{"nctId":"NCT00834873","phase":"PHASE1","title":"Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2001-12","conditions":"Healthy","enrollment":24},{"nctId":"NCT00648622","phase":"PHASE1","title":"Fed Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-04","conditions":"Healthy","enrollment":50},{"nctId":"NCT00650416","phase":"PHASE1","title":"Fasting Study of Carvedilol Tablets 12.5 mg to Coreg® Tablets 12.5 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2004-03","conditions":"Healthy","enrollment":50},{"nctId":"NCT04111133","phase":"NA","title":"Ivabradine in Cirrhotic Cardiomyopathy","status":"UNKNOWN","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2020-01-01","conditions":"Cirrhotic Cardiomyopathy, Left Ventricular Dysfunction, Cirrhosis, Liver","enrollment":130},{"nctId":"NCT01798992","phase":"PHASE4","title":"Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2000-09","conditions":"Idiopathic Dilated Cardiomyopathy","enrollment":56},{"nctId":"NCT05893849","phase":"","title":"Pharmacokinetics of Clinical Probes and Characteristics of Endogenous Biomarker in Chinese Older Adults","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-28","conditions":"Aging","enrollment":624},{"nctId":"NCT04049786","phase":"PHASE4","title":"Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol","status":"UNKNOWN","sponsor":"Natalia Valadares de Moraes","startDate":"2019-06-01","conditions":"Obesity, Bariatric Surgery, Roux-en Y Gastric Bypass","enrollment":120},{"nctId":"NCT05021406","phase":"NA","title":"Extension Study of Carvedilol RCT Study","status":"UNKNOWN","sponsor":"Beijing Friendship Hospital","startDate":"2021-01-08","conditions":"Liver Cirrhosis, Portal Hypertension","enrollment":240},{"nctId":"NCT02391337","phase":"PHASE4","title":"Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2016-12-20","conditions":"Permanent Atrial Fibrillation","enrollment":161},{"nctId":"NCT02045459","phase":"NA","title":"Microvascular Disease Exercise Trial","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2014-05","conditions":"Coronary Microvascular Disease","enrollment":79},{"nctId":"NCT03071653","phase":"PHASE2","title":"Left Cardiac Sympathetic Denervation for Cardiomyopathy Feasibility Pilot Study","status":"SUSPENDED","sponsor":"University of Cape Town","startDate":"2016-11-24","conditions":"Dilated Cardiomyopathy, Ischemic Cardiomyopathy, Non-ischemic Cardiomyopathy","enrollment":30},{"nctId":"NCT02907749","phase":"PHASE4","title":"Spironolactone on Fibrosis Progrssion-Portal Hypertension(FP-PH)in Cirrhosis","status":"COMPLETED","sponsor":"Changqing Yang","startDate":"2018-01-01","conditions":"Cirrhosis, Portal Hypertension","enrollment":96},{"nctId":"NCT02925975","phase":"PHASE4","title":"Early Precise Diagnosis and Intervention of CPT Based on a Noninvasive 3D-vHPS","status":"UNKNOWN","sponsor":"Changqing Yang","startDate":"2015-01","conditions":"Portal Hypertension, Cirrhosis","enrollment":100},{"nctId":"NCT03867994","phase":"PHASE2","title":"Comparison of Carvedilol and Atorvastatin for Preventing of Contrast-Induced Nephropathy.","status":"COMPLETED","sponsor":"rabab ahmed mohamed","startDate":"2016-02-01","conditions":"Contrast-induced Nephropathy","enrollment":144},{"nctId":"NCT01270672","phase":"NA","title":"Pharmacological Interaction Between Carvedilol and Methylenedioxymethamphetamine (MDMA)","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2011-01","conditions":"Mood Disorder, Substance-Related Disorders, Amphetamine-Related Disorders","enrollment":16},{"nctId":"NCT00741585","phase":"PHASE4","title":"Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment","status":"COMPLETED","sponsor":"University of Vigo","startDate":"2008-09-01","conditions":"Essential Hypertension, Cardiovascular Disease, Stroke","enrollment":21983},{"nctId":"NCT01862497","phase":"","title":"Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-01","conditions":"Intradialytic Hypertension","enrollment":76},{"nctId":"NCT01793870","phase":"PHASE1","title":"A Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-15","conditions":"Metabolic, Cardiovascular","enrollment":17},{"nctId":"NCT02148991","phase":"","title":"Clinical Trial in Patients With Hypertension and Left Ventricular Dysfunction","status":"COMPLETED","sponsor":"Elpen Pharmaceutical Co. Inc.","startDate":"2014-07","conditions":"Hypertension, Cardiac Arrhythmias, Diabetes Mellitus","enrollment":100},{"nctId":"NCT01774656","phase":"PHASE4","title":"Remission From Stage D Heart Failure","status":"UNKNOWN","sponsor":"University of Louisville","startDate":"2013-01","conditions":"Heart Failure NYHA Class III, Heart Failure NYHA Class IV","enrollment":40},{"nctId":"NCT02975323","phase":"PHASE3","title":"Doppler Ultrasound Hepatic Vein Waveform as a Non-invasive Tool in the Assessment of Severity of Portal Hypertension","status":"UNKNOWN","sponsor":"Aga Khan University","startDate":"2014-12","conditions":"Portal Hypertension","enrollment":50},{"nctId":"NCT02832089","phase":"PHASE3","title":"Oral Carvedilol in Escalating Doses in the Acute Treatment of Atrial Fibrillation","status":"COMPLETED","sponsor":"Andhra Medical College","startDate":"2000-12","conditions":"Atrial Fibrillation","enrollment":30},{"nctId":"NCT01815762","phase":"NA","title":"Extravascular Lung Water Monitoring by Combined Ultrasound and Bioimpedance as a Guide for Treatment in Hemodialysis Patients","status":"COMPLETED","sponsor":"Grigore T. Popa University of Medicine and Pharmacy","startDate":"2013-03","conditions":"Patients on Hemodialysis for More Than 3 Months","enrollment":250},{"nctId":"NCT01316952","phase":"","title":"Coreg and HSRs-Updated Analysis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Hypersensitivity","enrollment":1},{"nctId":"NCT01577914","phase":"PHASE1","title":"Bioequivalence Study of Carvedilol Tablets USP 12.5 mg Under Fasting Condition","status":"COMPLETED","sponsor":"IPCA Laboratories Ltd.","startDate":"2011-07","conditions":"Fasting State","enrollment":42},{"nctId":"NCT00391846","phase":"PHASE4","title":"Evaluation of Heart Failure Treatment Guided by N-terminal Pro B-type Natriuretic Peptide (NTproBNP) vs Clinical Symptoms and Signs Alone","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-10","conditions":"Heart Failure, Ventricular Dysfunction, Left","enrollment":252},{"nctId":"NCT01369472","phase":"PHASE1","title":"Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-06","conditions":"Chronic Stable Angina","enrollment":30},{"nctId":"NCT01340248","phase":"PHASE1","title":"A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2011-07","conditions":"Chronic Stable Angina","enrollment":24},{"nctId":"NCT00552708","phase":"PHASE1","title":"A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Hypertension","enrollment":55},{"nctId":"NCT00557128","phase":"PHASE1","title":"Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Hypertension","enrollment":24},{"nctId":"NCT00549510","phase":"PHASE1","title":"Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hypertension","enrollment":29},{"nctId":"NCT00556920","phase":"PHASE1","title":"Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hypertension","enrollment":50},{"nctId":"NCT00864149","phase":"PHASE1","title":"A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Non-fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-10","conditions":"Healthy","enrollment":36},{"nctId":"NCT00864435","phase":"PHASE1","title":"A Relative Bioavailability Study of Carvedilol 12.5 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Actavis Inc.","startDate":"2005-10","conditions":"Healthy","enrollment":36},{"nctId":"NCT00776113","phase":"NA","title":"Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2003-08","conditions":"Healthy","enrollment":40},{"nctId":"NCT00775619","phase":"NA","title":"Bioequivalence Study of Carvedilol 12.5mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Ranbaxy Laboratories Limited","startDate":"2003-09","conditions":"Healthy","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":175,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Carvedilol alone","genericName":"Carvedilol alone","companyName":"Taipei Veterans General Hospital, Taiwan","companyId":"taipei-veterans-general-hospital-taiwan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carvedilol is a small molecule that acts as an antagonist to the adrenergic receptor beta. It is used in clinical studies for various conditions including aging, liver cirrhosis, and esophageal and gastric varices.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}